Literature DB >> 10665940

Race is a major determinant of secondary hyperparathyroidism in uremic patients.

Ajay Gupta1, Lee R Kallenbach2, Gerard Zasuwa1, George W Divine2.   

Abstract

In the general population, blacks have higher parathyroid gland mass and circulating parathyroid hormone (PTH) levels than whites. This may predispose black patients to more severe parathyroid disease when renal failure develops. Therefore, racial differences in the severity of uremic hyperparathyroidism were examined in a population of patients with end-stage renal disease (ESRD). Among ESRD patients receiving hemodialysis or peritoneal dialysis, two or more values of intact PTH (immunoradiometric assay, pg/ml) obtained at least 90 d apart were available in 1270 prevalent cases (61.1% blacks, 51% males, and 31.1% diabetic), including 466 incident cases with onset of ESRD after 1993. Maximum PTH levels were analyzed as a function of race, gender, age, diabetic status, and levels of serum calcium, phosphorus, alkaline phosphatase, and aluminum. Using a stepwise multiple regression model, the determinants of maximum PTH in the order of their importance were black race, serum phosphorus, absence of diabetes, younger age, serum calcium, and female gender. The maximum PTH levels averaged 641.7 in blacks and 346.0 in whites after adjusting for age, gender, diabetic status, serum calcium, and phosphorus (P < 0.0001). In blacks compared with whites, the odds ratio (95% confidence interval) for adynamic bone disease (maximum PTH <150 pg/ml) was 0.26 (0.17 to 0.41), whereas the odds ratio for hyperparathyroid bone disease (mean PTH >500 pg/ml) was 4.4 (2.10 to 9.25). Race is a major independent determinant of uremic secondary hyperparathyroidism. Among ESRD patients, blacks may be at an increased risk for hyperparathyroid bone disease and whites for adynamic bone disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10665940     DOI: 10.1681/ASN.V112330

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  36 in total

1.  Impact of Race on the Association of Mineral Metabolism With Heart Failure: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Cassianne Robinson-Cohen; Michael Shlipak; Mark Sarnak; Ronit Katz; Carmen Peralta; Bessie Young; Andrew N Hoofnagle; Moyses Szklo; Joachim H Ix; Bruce M Psaty; Ian H de Boer; Bryan Kestenbaum; Nisha Bansal
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

2.  Impact of activated vitamin D and race on survival among hemodialysis patients.

Authors:  Myles Wolf; Joseph Betancourt; Yuchiao Chang; Anand Shah; Ming Teng; Hector Tamez; Orlando Gutierrez; Carlos A Camargo; Michal Melamed; Keith Norris; Meir J Stampfer; Neil R Powe; Ravi Thadhani
Journal:  J Am Soc Nephrol       Date:  2008-04-09       Impact factor: 10.121

3.  Timing of onset of CKD-related metabolic complications.

Authors:  Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray
Journal:  J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 10.121

4.  A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).

Authors:  James B Wetmore; Konstantin Gurevich; Stuart Sprague; Gerald Da Roza; John Buerkert; Maureen Reiner; William Goodman; Kerry Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-22       Impact factor: 8.237

Review 5.  Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society.

Authors:  Keith C Norris; Sandra F Williams; Connie M Rhee; Susanne B Nicholas; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; L Ebony Boulware
Journal:  Semin Dial       Date:  2017-03-09       Impact factor: 3.455

6.  Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Authors:  Pieter Evenepoel; Björn Meijers; Liesbeth Viaene; Bert Bammens; Kathleen Claes; Dirk Kuypers; Dirk Vanderschueren; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-06       Impact factor: 8.237

7.  Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.

Authors:  Julius U Okoye; Ejikeme B Arodiwe; Ifeoma I Ulasi; Chinwuba K Ijoma; Obinna D Onodugo
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

8.  Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.

Authors:  Julia J Scialla; Rulan S Parekh; Joseph A Eustace; Brad C Astor; Laura Plantinga; Bernard G Jaar; Tariq Shafi; Josef Coresh; Neil R Powe; Michal L Melamed
Journal:  Am J Nephrol       Date:  2015-08-20       Impact factor: 3.754

9.  Ethnicity, socioeconomic status, and attainment of clinical practice guideline standards in dialysis patients in the United kingdom.

Authors:  Udaya P Udayaraj; Yoav Ben-Shlomo; Paul Roderick; Retha Steenkamp; David Ansell; Charles R V Tomson; Fergus J Caskey
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 8.237

10.  Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients.

Authors:  Carol Moore; Jerry Yee; Hartmut Malluche; D Sudhaker Rao; Marie-Claude Monier-Faugere; Elizabeth Adams; Olufunmilola Daramola-Ogunwuyi; Hassan Fehmi; Saroj Bhat; Yahya Osman-Malik
Journal:  Clin J Am Soc Nephrol       Date:  2009-09       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.